NEW YORK (GenomeWeb News) – IncellDx today said it has reached a deal to offer its molecular diagnostic test for human papillomavirus in India.
Under the terms of the deal, New Delhi-based GeneCell Diagnostics will offer IncellDx's test for detecting oncogenic HPV E6, E7 mRNA through its laboratory partner CureHealth Diagnostics, which will be the first reference lab in India to offer the test.
IncellDx's technology uses a flow cytometry-based method to detect and quantify the expression of viral oncogenes that trigger progression to cervical cancer, providing higher specificity than other tests, according to the Menlo Park, Calif.-based firm.
"The high level of specificity our technology produces has a significant positive economic impact on healthcare delivery costs by potentially reducing the number of unnecessary colposcopy/biopsies," IncellDx Founder and CEO Bruce Patterson said in a statement.
Financial and other terms of the deal were not disclosed.
Earlier this month, IncellDx and Kindstar Global reached a deal to bring the HPV test to China.